Citations

Clear

1446 citation(s) found for "Howard, F".

Abstract CT076: Multicenter phase II study of nivolumab in previously treated patients with recurrent and metastatic non-keratinizing nasopharyngeal carcinoma - Mayo clinic Phase 2 Consortium P2C-MN026, NCI9742, NCT02339558
Ma, Brigette , Lim, Wan T., Riess, Jonathan W. , Agulnik, Mark , Chang, Alex Y. , Kish, Julie A., Lim, Dean, Cullen, Kevin J., Gitlitz, Barbara J. , Foster, Nathan R. , Pettinger, Adam, McKinzie, Sanna, To, Ka‐Fai , Costello, Brian A. , Streicher, Howard , Goh, Boon Cher , Lim, Wan T., Lo, Kwok Wai , Hui, Edwin Pun , Adkins, Douglas R. , Chan, Anthony T.�C. , Ma, Brigette B Y

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: CT076-CT076

10.1158/1538-7445.am2017-ct076 Get It

Abstract Background: Endemic nasopharyngeal carcinoma (NPC) refers to non-keratinizing (NK) subtypes harboring Epstein Barr virus (EBV) that frequently express programmed death-ligand 1 (PD-L1). We recently reported ≥30% of NPC harbor MHC class 1 gene alterations in a whole genome study. Method: We investigated the activity of nivolumab (NIVO) & relationship with PD-L1 & HLA expression (exp) in tumor cells (TC) & tumor infiltrating cells (TIL). Eligible patient (pt)s had to fail ≥ 1 prior line of platinum-based chemo. NIVO (3mg/kg IV, q2 weeks) was given until disease progression (PD). Archived tumors were analyzed for PD-L1 (DAKO) & HLA mutations (indicated by loss of HLA-A &/or B exp). Result: A total of 45 pts were enrolled across 11 sites from Oct 2015 to June 2016. Overall, 43 and 44 pts were evaluable respectively for response rate (RR, RECIST) & adverse events (AE). The median age was 57 years, 77% pts were males & 84% were Asians. The median number of prior chemo was 3 (range 1-9 lines). Of the 43 evaluable pts, there were 8 confirmed (19%, 95% CI: 8-33%) & 1 unconfirmed partial response (PR), 17 PD (40%), 14 stable disease (SD, 33%) & 3 pts were not assessed. One pt (MD015-027) had an unconfirmed clinical CR in an occipital metastasis (met). Pts received a median of 3 cycles of NIVO (range 1 - 14). Median overall survival has not been reached yet. Of the 44 pts evaluable for AE, 8 (18.2%) had grade 3 or higher treatment-related AEs & 1 pt died of sepsis. The most common grade 3 or higher AEs were increase in alanine/aspartate aminotransferase (n=3), & 1 pt respectively for hyponatremia, neutropenia, fatigue & diarrhea. Of the 21 tumor samples analyzed, 11/21 (52%) had >1% PD-L1 expressed mainly in TC. Table 1 outlines relationship between RR & PD-L1 exp. All pts with PR had >5% PD-L1 exp & one pt (34003-022) with CR (nasopharynx) & PR (lung mets) had the highest exp (80%). Majority of pts with PD had <1% PD-L1 exp tumors. One primary progressor (34003-032) had a PD-L1 +ve tumor harboring a complete loss of HLA-B signal (TC), but intact signal in TILs & stromal cells. Conclusion: NIVO is active in this heavily pre-treated group of pts with NK-NPC and longer follow-up is needed for survival endpoints. Preliminary result suggests PD-L1 exp may predict benefit from NIVO. The analytical result of all 45 tumors will be presented. Table 1.PD-L1 exp and RECIST response in 21 ptsPD-L1%espRR%PRSDPD0-11<1%-265%24-10%--120%-1-30%11-80%1--Total498 Citation Format: Brigette B. Ma, Boon Cher Goh, Wan T. Lim, Kwok W. Lo, Edwin P. Hui, Jonathan W. Riess, Mark Agulnik, Alex Y. Chang, Julie A. Kish, Dean W. Lim, Douglas R. Adkins, Kevin J. Cullen, Barbara J. Gitlitz, Nathan R. Foster, Adam M. Pettinger, Sanna Mckinzie, Ka F. To, Brian Costello, Howard Streicher, Anthony T. Chan. Multicenter phase II study of nivolumab in previously treated patients with recurrent and metastatic non-keratinizing nasopharyngeal carcinoma - Mayo clinic Phase 2 Consortium P2C-MN026, NCI9742, NCT02339558 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr CT076. doi:10.1158/1538-7445.AM2017-CT076
Obstruction of the Lower Third of the Ureter by Anomalous Blood Vessels
Greene, Laurence F., Priestley, James T., Simon, Howard B., Hempstead, Richard H.

Mayo Clinic

Journal of Urology | July 12, 2017 | Volume: 71 | Issue: 5 | Pages: 544-548

10.1016/s0022-5347(17)67823-6 | PMID 13152881 Get It

Further Observations on the Electrolyte Pattern of the Blood After Bilateral Ureterosigmoidostomy
Odel, Howard M., Ferris, Deward O., Priestley, James T.

Mayo Clinic

Journal of Urology | July 12, 2017 | Volume: 65 | Issue: 6 | Pages: 1013-1020

10.1016/s0022-5347(17)68587-2 | PMID 14841844 Get It

Antibiotic Prophylaxis in Transurethral Prostatic Resection: A Clinical Study
Simon, Howard B., Jeremias, Martin T., Greene, Laurence F., Geraci, J E

Mayo Clinic

Journal of Urology | July 11, 2017 | Volume: 74 | Issue: 1 | Pages: 123-128

10.1016/s0022-5347(17)67253-7 | PMID 13243511 Get It

Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer
Stroup, Sean P. , Moreira, Daniel M. , Chen, Zinan, Howard, Lauren E. , Berger, Jonathan , Amling, Christopher L. , Freedland, Stephen J. , Terris, Martha K. , Aronson, William J. , Cooperberg, Matthew R , Kane, Christopher J. , Howard, Lauren E

Mayo Clinic

Journal of Urology | July 11, 2017 | Volume: 198 | Issue: 6 | Pages: 1309-1315

10.1016/j.juro.2017.07.009 | PMID 28709888 Get It

Simple Renal Cysts in Children: Review of the Literature and Report of Five Cases
DeWeerd, James H., Simon, Howard B.

Mayo Clinic

Journal of Urology | July 11, 2017 | Volume: 75 | Issue: 6 | Pages: 912-921

10.1016/s0022-5347(17)66904-0 | PMID 13320587 Get It

Renal Papillary Necrosis: A Clinicopathologic Study of 42 Cases
Simon, Howard B., Bennett, Warren A. , Emmett, John L.

Mayo Clinic

Journal of Urology | July 11, 2017 | Volume: 77 | Issue: 4 | Pages: 557-567

10.1016/s0022-5347(17)66599-6 | PMID 13417291 Get It

Autotransfusion: Urologic Applications and the Development of a Modified Irrigating Fluid
Wilson, John D. , Taswell, Howard F., Utz, David C.

Mayo Clinic

Journal of Urology | July 10, 2017 | Volume: 105 | Issue: 6 | Pages: 873-877

10.1016/s0022-5347(17)61651-3 | PMID 5091719 Get It

BIOLOGICAL MARKERS IN FAMILY RESEARCH
Bangerter, L., Zarit, Steven Howard

Mayo Clinic

Innovation in Aging | June 30, 2017 | Volume: 1 | Issue: suppl_1 | Pages: 11-11

10.1093/geroni/igx004.038 Get It

Transurethral Prostatic Resection in Patients with Myasthenia Gravis
Greene, Laurence F., Ghosh, Manas K., Howard, F

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 112 | Issue: 2 | Pages: 226-227

10.1016/s0022-5347(17)59693-7 | PMID 4843338 Get It